June 2025 Activities Report and Appendix 4C

Highlights of the Quarter:

- **U.S FDA Grants Fast Track designation for PTX-100**
- **Fast Track unlocks several benefits including increased access to FDA and rolling submissions of New Drug Application; potential for faster and more efficient product development of PTX-100 in CTCL**
- **First patient dosed in randomized Phase 2a clinical trial representing a key milestone in the development of PTX-100 as a potential treatment for Cutaneous T-Cell Lymphoma (CTCL)**
- **Melanie Farris joins as independent Non-Executive Director**
- **Cash balance of $6.9 million at 30 June 2025**
- **Spending in line with budget**

MELBOURNE Australia, 30 July 2025: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing targeted therapies for cancer, today reported its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the June 2025 quarter.

Financial summary

Prescient ended the quarter with cash reserves of $6.9 million ($10.2 million on 31 March 2025). Net operating cash outflow during the quarter was $3.3 million. Total operating expenditure for the quarter was $3.3 million, with $2.2 million invested in R&D and clinical activities.

Payments to related parties of the entity and their associates of $79,000 related to non-executive director fees.

PTX-100 activity summary

The U.S. FDA has granted Fast Track Designation for PTX-100 in the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. This marks another milestone for PTX-100 on the pathway to treating patients suffering with r/r Cutaneous T Cell Lymphoma (CTCL).

Fast Track is a process designed by the FDA to expedite the review of therapies that treat serious conditions with a high unmet need, with the aim of getting therapies to patients faster. It provides several benefits including increased access to the FDA, the possibility of rolling submissions of New Drug Applications and a pathway to expedited approval – a key element of Prescient's PTX-100 strategy.

The granting of Fast Track designation at this stage signifies that, despite other therapies being currently available in the U.S., the FDA recognises that data from a prior completed PTX-100 clinical study indicates promise as a potential treatment option for an unmet medical need.

The first patient has been dosed in Prescient's Phase 2a clinical study of PTX-100. This is a key milestone representing significant progress in advancing PTX-100 as a potential treatment for patients with CTCL, building on the positive results from the Phase 1 study.

The Phase 2a clinical study will evaluate two dosage levels of PTX-100 in an open-label randomized design, enrolling a total of approximately 40 patients with relapsed/refractory (r/r) Cutaneous T Cell Lymphoma (CTCL). The study's primary endpoint is efficacy, with safety among the secondary endpoints.

The Prescient team continues the process of initiating trial sites for the study in Australia, the United States and Europe, and the study plan envisages that up to 16 sites may be activated. As of 30 June 2025, two sites had been initiated in Australia, with additional sites planned for opening in Australia and the U.S. in the month of July.

Prescient retains ongoing interest in Peripheral T Cell Lymphoma (PTCL) and is exploring ways to generate additional clinical data for PTX-100 in this patient population.

Cell therapy platforms

Prescient has initiated several collaborations involving CellPryme-M with potential partner companies to explore ways to enhance their cell therapy programs. Prescient will continue to update investors on the progress of these collaborations as material results become known.

After extensive troubleshooting to resolve certain OmniCAR technical issues and then engineering of new, improved molecular variants, development efforts have yielded positive results. Based on this progress, development efforts will continue, with further validation work required.

Non-Executive Director Appointment

During the quarter, Prescient announced the appointment of Melanie Farris to the Board as an independent Non-Executive Director.

Ms Farris brings extensive senior executive and board-level experience with a range of Australian biotechnology companies including Telix Pharmaceuticals Limited, Factor Therapeutics Limited and Invion Limited. She is a Member of the Ausbiotech QLD State Committee.

Ms Farris is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.

Ms Farris serves as Chair of the Audit and Risk Committee.

Subsequent Event

On 2 July 2025, the Company opened a Share Purchase Plan (SPP). The SPP closed on 25 July 2025 having raised $6.8 million.

The SPP bolsters Prescient's cash balance, which will be used to support the advancement of the Company's first-in-class cancer treatment PTX-100, specifically by funding the current Phase 2 clinical trial and continued clinical development of this targeted therapy. The Company is working to progress this potential therapy through clinical trials and toward regulatory approval and access for patients with significant unmet medical needs.

On the 29 July 2025 the Company entered a trading halt for a follow-on Placement to sophisticated and professional investors.

- Ends -

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor enquiries

Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the phase 2a part of the trial.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance

or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Prescient Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
56 006 569 106	30 June 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(2,150)	(6,953)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(501)	(1,510)
	(f) administration and corporate costs	(611)	(2,782)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	3	339
1.5	Interest and other costs of finance paid		(10)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	3,712
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(3,259)**	**(7,204)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	(3)	(8)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(j) investments in term deposits with maturities longer than 3 months at acquisition	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments (term deposits)	-	4,000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(3)**	**3,992**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(330)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**-**	**(330)**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	10,198	10,492
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,259)	(7,204)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	3,992
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(330)
4.5	Effect of movement in exchange rates on cash held	(28)	(42)
4.6	**Cash and cash equivalents at end of period**	**6,908**	**6,908**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	6,908	10,198
5.2	Call deposits*	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**6,908**	**10,198**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	79
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Premium financing)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,259)
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,908
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	6,908
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**2.12**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: N/A	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	N/A	
	Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.	

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2025

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.